Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 5,230

Document Document Title
WO/2017/210685A1
The present disclosure is directed to pyridazin-3(2H)-one compounds of formula (I), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treati...  
WO/2017/202816A1
The present invention covers 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds u...  
WO/2017/199028A1
A method of preparing an active agent or a salt thereof from a prodrug first compound (1) comprising a propargyl group connected to an oxygen that is directly or indirectly connected to the active agent is provided, wherein the bond betw...  
WO/2017/193034A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2017/191000A1
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...  
WO/2017/193041A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2017/192665A1
This disclosure relates to inhibitors of IRES-mediated protein synthesis, compositions comprising therapeutically effective amounts of these compounds, and methods of using those compounds and compositions in treating hyperproliferative ...  
WO/2017/193063A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2017/181918A1
The present invention discloses a substituted phthalazone, wherein the substituted phthalazone is a compound represented by formula (I). The invention further discloses a pharmaceutical composition comprising the compound, or a crystalli...  
WO/2017/178582A1
The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein A1, R1, Ra, Rb, Rc and Rd are as defined herein. The invention further relates to herbicidal compositions which comp...  
WO/2017/170759A1
Provided is a novel herbicide having a significant herbicidal activity against undesirable plants. A pyridazinone-type compound represented by general formula (I) (wherein X represents -O-, -S-, -SO-, -SO2- or -N(Y)-; Q represents a mono...  
WO/2017/160569A1
The present disclosure provides pyrimidine compounds and uses thereof, for example, for the treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonist...  
WO/2017/156181A1
The present invention provides compounds, compositions thereof, and methods of using the same.  
WO/2017/153958A1
The present invention provides crystalline Form M of Olaparib, amorphous form of Olaparib, process for their preparation, pharmaceutical composition thereof and their use as medicaments.  
WO/2017/156179A1
The present invention provides compounds, compositions thereof, and methods of using the same.  
WO/2017/156165A1
The present invention provides compounds, compositions thereof, and methods of using the same.  
WO/2017/156177A1
The present invention provides compounds, compositions thereof, and methods of using the same.  
WO/2017/153518A1
A compound of formula (Ia), (Ib) or (Ic) wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2O...  
WO/2017/150654A1
The present invention provides an agent for treating malignant tumor, comprising a compound of formula (1): wherein R1 to R4 are hydrogen atom, halogen, or etc., Y is optionally-substituted alkylene group or etc.  
WO/2017/147701A1
The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibit...  
WO/2017/140422A1
A new method for producing a crystalline form of 5-amino-2,3-dihydro-1,4-phthalazinedione (luminol) is provided. Advantageous uses for this crystalline form as a detecting agent or as an agent for forensic purposes are disclosed, as well...  
WO/2017/140430A1
A new crystalline form of 5-amino-2,3-dihydro-1,4-phthalazinedione (luminol) is provided. Advantageous uses for this crystalline form as a detecting agent or as an agent for forensic purposes are disclosed, as well a pharmaceutical compo...  
WO/2017/140283A1
The invention relates to solvated crystalline forms of olaparib of formula I, with the systematic name 4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl)-4-flu orophenyl]methyl(2H)- phtalazin-1-one, a method of their preparation and ...  
WO/2017/131221A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions cont...  
WO/2017/123156A1
In certain aspects, the invention provides crystalline forms of olaparib (4-[(3-[(4- cyclopropylcarbonyl)piperazin-4-yl]carbonyl)-4-fluorophenyl] methyl(2H)phthalazin- 1 -one). In related aspects, the invention provides processes for pre...  
WO/2017/106634A1
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders...  
WO/2017/090655A1
The present invention provides a pest control composition which includes a compound represented by formula (1) (in the formula, each symbol is as defined in the description) or an N-oxide compound thereof, and at least one compound selec...  
WO/2017/074988A1
Disclosed is a process for preparing a compound of Formula 1, from a compound of Formula 2 wherein X, R1, R2, R3, R4, R5, n, R6, R7, G and W are as defined in the disclosure. Also disclosed are compounds of Formulae 2 and 4 wherein X, R1...  
WO/2017/069226A1
A compound represented by general formula [I] (in the formula, X represents N or the like, Y represents CH or the like, RA represents an optionally substituted cycloalkyl group or the like, R1 represents an alkyl group or the like, R2 re...  
WO/2017/061288A1
Provided is a method for measuring tyrosine phosphatase and tyrosine kinase activity, as a high-sensitivity measuring method, which is suitable for high throughput and which uses a compound represented by general formula (I) (in the form...  
WO/2017/059085A1
The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAKl (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's dis...  
WO/2017/054765A1
The present invention relates to a benzamide derivative of general formula I, a drug composition containing same and a use thereof as a drug, wherein the definitions of R1, Z and Q are as described in the description.  
WO/2017/049192A1
The disclosure relates to methods and compositions for reactivating a silenced FMR1 gene. In some aspects, methods described by the disclosure are useful for treating a FMR1- inactivation-associated disorder (e.g., fragile X syndrome).  
WO/2017/036404A1
Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine ...  
WO/2017/038873A1
The purpose of the present invention is to provide a compound having inhibitory activity with respect to the discoidin domain receptor 1. The present invention provides a urea derivative represented by the formula below or a pharmacologi...  
WO/2017/036266A1
Provided are 3-aryl pyridazinone as shown by formula I, and a preparation method, pesticide composition and use. The 3-aryl pyridazinone provided has a highly-efficient herbicidal activity, a relatively broad phytocidal range, good crop ...  
WO/2017/037146A1
The invention provides novel compounds having the general formula (I), wherein RA, RB, RC, RC1 and W are as defined herein, compositions including the compounds and methods of using the compounds.  
WO/2017/028798A1
Disclosed are a pyridazinone compound as shown in the following general formula I or a pharmaceutically acceptable salt, a preparation method, a pharmaceutical composition and a use thereof in the preparation of a hepatitis B virus inhib...  
WO/2017/023992A1
The present invention provides compounds of Formula (I): [INSERT CHEMICAL STRUCTURE HERE] (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are...  
WO/2017/012922A1
The invention relates to substituted cyclic aryl and heteroaryl carboxylic acid hydrazides of general formula (I) or salts thereof, wherein the groups of formula (I) have the definitions stated in the description, for increasing the stre...  
WO2017010399A1
Provided are compounds having RORγt inhibitory effects represented by formula (I). Compounds represented by formula (I) (wherein L represents -NR1ACO-, -SO2- or the like, A represents a substituted or unsubstituted aromatic carbocyclic ...  
WO/2016/198507A1
Compound of formula (I) wherein A is selected from (i), where RF1 is H or F; (ii); (iii) a N-containing C6 heteroaryl group; and B is (B), where X1 is either CRF2 or N, where RF2 is H or F; X2 is either CR3 or N, where R3 is selected fro...  
WO/2016/195077A1
This novel guanidine compound having excellent bactericidal activity is represented by formula [I]. (In the formula, Y represents a divalent group represented by formula [II] (wherein each of R7-R9 independently represents a hydrogen ato...  
WO/2016/187620A3
This invention provides, among other things, compounds useful for treating diseases such as cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeuti...  
WO/2016/187620A2
This invention provides, among other things, compounds useful for treating diseases such as cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeuti...  
WO/2016/180833A1
The present invention relates to a process for preparing a pyridazine amine compound of formula V, and to processes for preparing dichloropyridazine amine compounds of formula IVa, IVb, or mixtures thereof. Furthermore, the present inven...  
WO/2016/177710A1
Compounds of formula I, or pharmaceutical salts thereof, wherein R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.  
WO/2016/177760A1
Compounds of formula I: or pharmaceutical salts thereof, wherein m, A, X, Y, Z, R1, R2, R3, R4 and R5are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases...  
WO/2016/168059A1
This disclosure relates to the field of moiecuies having pesticida i utility against pests in Phyla Arthropoda, Moliusca, and hJematoda, processes to produce such moiecuies, intermediates used In such processes, pesticidai compositions c...  
WO/2016/165650A1
Disclosed are a co-crystal of olaparib and urea and a preparation method therefor. Specifically disclosed is a co-crystal form A, and an X-ray powder diffraction pattern of this crystal form has characteristic peaks at points where 2thet...  

Matches 1 - 50 out of 5,230